GLP-1 Weight Loss Drugs May Reshape Consumer Spending, Analysis Finds

A new analysis suggests that widely used Ozempic, Wegovy, and Zepbound could have effects far beyond treating medical conditions.

The medications belong to a class of drugs known as GLP-1 receptor agonists, which are commonly prescribed to treat Type 2 Diabetes and Obesity. But experts say their growing popularity may also be reshaping consumer behavior.

According to a recent analysis by PwC, people taking GLP-1 medications are changing how they eat, shop, exercise, and travel. Businesses across several industries—from restaurants to fitness companies—are beginning to adjust their offerings to meet new customer habits.

Some restaurants have even introduced special menus designed for people taking the medications, focusing on smaller portions with higher protein and fiber content.

Analysts say the broader impact could continue expanding as the medications become more widely available, potentially influencing household purchasing decisions and the overall consumer economy.

Experts describe the shift as one of the most significant consumer behavior trends in recent years, with ripple effects that could reshape industries well beyond healthcare.